Baird Medical Investment Holdings Limited BDMD PHARMA
Company Overview
Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation. It sells its products through third-party distributors. It has a strategic cooperation agreement with Tianjin Yuanshan Medical Technology Co., Ltd. to focus on global development and commercialization of next-generation IRE technologies. Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.
Recent Developments
- Dec 2025 Revenue of $22.54M (-39.2% YoY); net profit $-27.28M.
- Trailing 12 Months Year-on-year growth — revenue +24.6%, earnings -319.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -13.7%, profit CAGR -105.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -13.72% |
| 1 Year: | 24.60% |
Compounded Profit Growth
| 5 Years: | -105.68% |
| 1 Year: | -319.04% |
Stock Price Performance
| 1 Year: | -59.85% |
| 6 Months: | -61.67% |
| 3 Months: | -14.06% |
| 1 Month: | -9.84% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -13.7% CAGR over 5 years.
- Earnings shrank at -105.7% CAGR over 5 years.
- Trading 68.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BDMD Baird Medical Investment Holdings Limited PHARMA | 1.10 | -2.00 | $35.18M | 0.00% | -68.66% | -46.03% | -13.72% | -105.68% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 35.09M | 31.46M | 37.04M | 22.54M |
| Cost of Revenue | - | 7.05M | 4.23M | 4.38M | 3.65M |
| Gross Profit | - | 28.04M | 27.23M | 32.65M | 18.88M |
| Operating Expenses | - | 13.03M | 14.58M | 17.34M | 44.42M |
| Operating Income | - | 15.01M | 12.65M | 15.32M | -25.54M |
| EBITDA | - | 16.29M | 13.66M | 15.80M | -24.53M |
| Interest Expense | - | 299.27K | 284.27K | 576.36K | 737.37K |
| Pretax Income | - | 14.52M | 12.36M | 14.09M | -26.37M |
| Tax Provision | - | 1.75M | 1.70M | 1.49M | 1.17M |
| Net Income | - | 12.57M | 10.55M | 12.45M | -27.28M |
| Diluted EPS | 0.39 | 0.49 | 0.41 | 0.57 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 42.62M | 56.71M | 77.96M | 69.70M |
| Current Assets | - | 33.76M | 40.08M | 61.42M | 54.97M |
| Cash & Equivalents | - | 1.71M | 1.51M | 2.97M | 178.32K |
| Inventory | - | 1.29M | 1.14M | 1.30M | 1.09M |
| Receivables | - | 24.37M | 31.10M | 46.58M | 42.53M |
| Total Liabilities | - | 16.84M | 21.00M | 38.20M | 38.48M |
| Current Liabilities | - | 16.02M | 18.98M | 34.62M | 32.36M |
| Long Term Debt | - | - | 1.61M | 3.44M | 6.09M |
| Total Debt | - | 7.44M | 11.51M | 20.88M | 19.30M |
| Total Equity | - | 25.93M | 35.75M | 39.66M | 31.37M |
| Shares Outstanding | - | 35.45M | 25.56M | 35.73M | 40.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 485.97K | -1.02M | -6.31M | -1.34M |
| Investing Cash Flow | - | -5.92M | -2.65M | -2.47M | -42.31K |
| Financing Cash Flow | - | 4.41M | 3.48M | 10.33M | -1.39M |
| Capital Expenditure | - | -5.95M | -2.64M | -2.85M | -42.31K |
| Free Cash Flow | - | -5.47M | -3.66M | -9.17M | -1.39M |
| Net Change in Cash | - | -1.02M | -197.33K | 1.55M | -2.78M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 79.9% | 86.6% | 88.2% | 83.8% |
| Operating Margin % | - | 42.8% | 40.2% | 41.4% | -113.3% |
| Net Margin % | - | 35.8% | 33.5% | 33.6% | -121.0% |
| ROE % | - | 48.5% | 29.5% | 31.4% | -87.0% |
| ROCE % | - | 56.4% | 33.5% | 35.3% | -68.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | 0.14% | 58.69K | $61.62K |
| 2 | Renaissance Technologies, LLC | 0.13% | 55.37K | $58.14K |
| 3 | Two Sigma Investments, LP | 0.13% | 55.50K | $58.27K |
| 4 | Citadel Advisors Llc | 0.13% | 54.90K | $57.64K |
| 5 | National Bank of Canada/FI/ | 0.07% | 28.48K | $29.91K |
| 6 | Jane Street Group, LLC | 0.07% | 31.57K | $33.15K |
| 7 | Geode Capital Management, LLC | 0.05% | 19.60K | $20.57K |
| 8 | Xtx Topco Ltd | 0.03% | 11.17K | $11.73K |
| 9 | Caitong International Asset Management Co., Ltd | - | 4 | $4 |
| 10 | Wolverine Asset Management, LLC | - | 205 | $215 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BDMD
An $11.4 million loss became a $13,499 profit at Baird Medical - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPbU9UUk1Fc1FQdHJjUHMweEx3VFk3c1JKZmQyc1g1a1JmQ0JTam9VMWxWbUtmcnY1M19qakFDTU5CTG8yTElDeUI5c1paTGh1OHplZ1pUdGZsLThMQ0Y3QjA0b2YxaEVCdG9IbU1sTGNYeFVVVUVuYV9fNmV3QlhoTjNzLTdvMU9kX1hhOH…
BDMD - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5sYmV6TkhHMkdkQ3hQbURWTS1ZcXU3bk1oX2VzcHRJTzJjdk5wNlZ2OHVPakhsM3ctNWdXWGl5U0ZCcVNLbWc?oc=5" target="_blank">BDMD</a> <font color="#6f6f6f">Finviz</font>…
BDMD Stock Surges Amid Strategic Moves and Market Dynamics - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPdVVHLWJQZTRIYnZlekVjbUFoV2YzYWJ0dUdJYkxSUUVyeUgzdnZ1d1dLNGxXMExvRktqelRCWU9xRXlmNmUyS1FpSmVnQlVKTGwxeGZKWGhMRDgyOFB4QndpMjduSndHUmt4QjV3ZVFMSUlNSm01eFB4NlgtOGdxODBJNEQtSlBFcmlVeE…
Enterprise value to EBITDA forward of Baird Medical Investment Holdings Ltd – NASDAQ:BDMD - tradingview.com
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNbWZXd0VHQk1YaVduRW4tdmpQWVk5eV9nQ2s5dENIcVNuemlnb3RaNVhlN3ZhVk5tSXNEOURIMFNRQUp0eEVGRmdFeWZBU21mV2w5Tlg1QWcxUjJzdGNiSjdmZV9SclRDRGNhYUJ5QmctWmszSlM0LVFKR3ZpN09XY0I4cndPRFNHbG5xM1…
Baird Medical Investment Holdings Limited (NASDAQ:BDMD) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNMHZKbUxydHdKSlN4U0R6Ul9razctc2F4N3hJUWlmQ1kwalhSektSTVZvWWphVFVMSmNVZEdXVmVaZWNPd0tKcWhSd1B5UHJCMHlYREhRVkxVMElrYW5lZTc5MVkxQ015WUZfcU9SQnA2ejBNREtQZnVISnNsbzE5eG10M0pBWnczLVFwQW…
Baird Medical Investment (BDMD) Stock Analysis Report | Financials & Insights - Benzinga España
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTFA5bkhpSlpiVnJQdURYSDZEUGpMdzYyOXVoY0FlZ1UxeUViaU1pb0pQZHI1aTJqcXZyc0I0THQ3MGQxa1k2b21pbTZZNVROSkl6UFMw?oc=5" target="_blank">Baird Medical Investment (BDMD) Stock Analysis Report |…
BDMD — Frequently Asked Questions
What is the current share price of Baird Medical Investment Holdings Limited (BDMD)?
As of 2026-09-19 21:16 PDT, Baird Medical Investment Holdings Limited (BDMD) trades at $1.10 on NasdaqCM. Its 52-week range is $0.77 to $3.44.
What is the market capitalisation of BDMD?
Baird Medical Investment Holdings Limited (BDMD) has a market capitalisation of $35.18M on NasdaqCM.
What is the P/E ratio of BDMD?
BDMD trades at a trailing price-to-earnings (P/E) ratio of -2.00. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.69.
What is the return on equity (ROE) of BDMD?
BDMD has a return on equity (ROE) of -46.03%. Its return on capital employed (ROCE) is -68.66%.
Is BDMD a good stock to buy?
This page provides a data-driven analysis of Baird Medical Investment Holdings Limited (BDMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.